Literature DB >> 31529281

Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.

Mario Tiribelli1, Elisabetta Abruzzese2, Isabella Capodanno3, Federica Sorà4, Elena Trabacchi5, Alessandra Iurlo6, Luigiana Luciano7, Gianni Binotto8, Massimiliano Bonifacio9, Mario Annunziata10, Monica Crugnola11, Renato Fanin12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31529281     DOI： 10.1007/s00277-019-03802-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  The CoV-2 outbreak: how hematologists could help to fight Covid-19.

Authors:  Sara Galimberti; Chiara Baldini; Claudia Baratè; Federica Ricci; Serena Balducci; Susanna Grassi; Francesco Ferro; Gabriele Buda; Edoardo Benedetti; Rita Fazzi; Laura Baglietto; Ersilia Lucenteforte; Antonello Di Paolo; Mario Petrini
Journal:  Pharmacol Res       Date:  2020-05-06       Impact factor: 7.658

2.  Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event.

Authors:  Raffaella Pasquale; Cristina Bucelli; Valentina Bellani; Manuela Zappa; Alessandra Iurlo; Daniele Cattaneo
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

3.  Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

Authors:  Qiuying Selina Liu; Nour Ali Ass'ad; Cecilia Arana Yi
Journal:  Clin Case Rep       Date:  2021-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.